Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

Valentin Fuster, MD, PhD, director of Mount Sinai Heart and general director of the Spanish National Center for Cardiovascular Research

Cardiologist Valentin Fuster named president of Mount Sinai Heart

The hugely influential doctor will still serve as the general director of the Spanish National Center for Cardiovascular Research and editor-in-chief of the Journal of the American College of Cardiology.

VIDEO: Role of PFO closure in stroke prevention

John Carroll, MD, director of interventional cardiology and professor of medicine at the University of Colorado, explains the state of  transcatheter closure of patent foramen ovale (PFO) to prevent stroke.

Industry insights: 4 healthcare executives discuss the biggest challenges in cardiology today

We spoke to executives from some of healthcare's most prominent vendors to find out what challenges are on their radar in 2022 and beyond. 

Impella Heart Pump Abiomed RECOVER IV RCT cardiogenic shock

Impella heart pumps boost survival up to 81% for cardiogenic shock patients

The heart pumps appear to provide significant benefits for patients with acute myocardial infarction- or myocarditis-related cardiogenic shock. 

The Medtronic Intrepid transcatheter mitral valve replacement (TMVR) system performed well in two studies presendted at TCT 2022. #TCT #TCT22 #TCT2022 #TMVR

Intrepid transcatheter mitral valve pilot study shows positive 3-year outcomes

New data on the Medtronic Intrepid transcatheter mitral valve replacement system from the Intrepid Pilot Study and Intermediate-Term Outcomes of the Intrepid Early Feasibility Study, were presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference.

Intravascular lithotripsy (IVL) Shockwave Medical PCI PAD CAD Disrupt PAD Disrupt CAD SCAI 2022

Is IVL equally effective in male and female patients? Shockwave Medical aims to find out with a historic new study

Shockwave announced at TCT 2022 that it hopes to enroll up to 400 patients for a new all-female clinical trial.

The Pulnovo pulmonary artery denervation catheter. In February 2021, the devices was granted the U.S. Food and Drug Administration (FDA) breakthrough device designation. #TCT2022 #PAH

Pulmonary artery denervation shows promise to treat pulmonary arterial hypertension

Pulmonary artery denervation may offer a new therapy option for this difficult-to-treat population.

The Pascal transcatheter mitral valve repair system. Similar to the latest version of the MitraClip, the Pascal can operate each leaflet independently to grasp the mitral valve leaflets. Results of the CLASP IID trial at #TCT2022.

Pascal transcatheter mitral repair device performs as well as MitraClip in late-breaking CLASP IID Trial 

Comparison between transcatheter edge-to-edge repair (TEER) devices found Pascal was non-inferior compared with MitraClip in the CLASP IID pivotal trial.